Literature DB >> 33191657

Clinicopathological features and prognostic implications of ASCL1 expression in surgically resected small cell lung cancer.

Jiacong Wei1, Li Liu1, Yiying Guo2, Jinyao Zhang2, Xin Wang1, Jiyan Dong1, Puyuan Xing2, Jianming Ying1, Lin Yang1, Junling Li2.   

Abstract

BACKGROUND: Small cell lung cancer (SCLC) is one of the most aggressive lung cancers. Treatment of SCLC has remained unchanged during the past decades. Preclinical studies have revealed ASCL1 as a transcription regulator in the neuroendocrine (NE) differentiation and carcinogenesis of SCLC. However, there are few studies on correlation of ASCL1 expression and clinicopathological factors in resected SCLCs. Here, we aimed to analyze the ASCL1 expression of SCLC and investigate its associations with clinicopathological factors and survival.
METHODS: A total of 247 surgically resected pure SCLC specimens were included in this retrospective study, all of which were processed using tissue microarrays for immunohistochemistry analysis of ASCL1. A total of 48 of 247 cases were tested by NanoString for mRNA expression analysis on 50 SCLC related genes. Statistical analysis was performed using R studio and SPSS software.
RESULTS: NE scores of 48 pure SCLC specimens were calculated by analyzing 50 preselected genes. A significant correlation between NE score with both ASCL1 mRNA expression and ASCL1 protein expression were observed. For the entire cohort of 247 patients, ASCL1 was highly expressed in 42.5% of pure SCLC patients according to IHC results. Significant differences were observed between ASCL1 high and low expression groups in variables including staging, lymph node metastasis, nerve invasion and overall survival.
CONCLUSIONS: In limited staged pure SCLC, ASCL1 expression was positively correlated with NE signature, pTNM stage, nerve invasion and OS. ASCL1 may therefore serve as a potential biomarker to predict prognosis as well as in the selection of patients for therapies targeting ASCL1-regulated downstream molecules.
© 2020 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  ASH1; NanoString; neuroendocrine tumors; small cell lung cancer (SCLC); tissue microarray

Year:  2020        PMID: 33191657      PMCID: PMC7779202          DOI: 10.1111/1759-7714.13705

Source DB:  PubMed          Journal:  Thorac Cancer        ISSN: 1759-7706            Impact factor:   3.500


  24 in total

Review 1.  Small-cell lung cancer: a review of clinical trials.

Authors:  Richard F Riedel; Jeffrey Crawford
Journal:  Semin Thorac Cardiovasc Surg       Date:  2003-10

2.  A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo.

Authors:  Laura R Saunders; Alexander J Bankovich; Wade C Anderson; Monette A Aujay; Sheila Bheddah; KristenAnn Black; Radhika Desai; Paul A Escarpe; Johannes Hampl; Amy Laysang; David Liu; Javier Lopez-Molina; Milly Milton; Albert Park; Marybeth A Pysz; Hui Shao; Brian Slingerland; Michael Torgov; Samuel A Williams; Orit Foord; Philip Howard; Jacek Jassem; Andrzej Badzio; Piotr Czapiewski; David H Harpole; Afshin Dowlati; Pierre P Massion; William D Travis; M Catherine Pietanza; J T Poirier; Charles M Rudin; Robert A Stull; Scott J Dylla
Journal:  Sci Transl Med       Date:  2015-08-26       Impact factor: 17.956

3.  ASH1 gene is a specific therapeutic target for lung cancers with neuroendocrine features.

Authors:  Hirotaka Osada; Yoshio Tatematsu; Yasushi Yatabe; Yoshitsugu Horio; Takashi Takahashi
Journal:  Cancer Res       Date:  2005-12-01       Impact factor: 12.701

4.  Characterization of variant subclasses of cell lines derived from small cell lung cancer having distinctive biochemical, morphological, and growth properties.

Authors:  A F Gazdar; D N Carney; M M Nau; J D Minna
Journal:  Cancer Res       Date:  1985-06       Impact factor: 12.701

5.  A subset of small cell lung cancer with low neuroendocrine expression and good prognosis: a comparison study of surgical and inoperable cases with biopsy.

Authors:  Wakako Hamanaka; Noriko Motoi; Shumpei Ishikawa; Masaru Ushijima; Kentaro Inamura; Satoko Hatano; Hirofumi Uehara; Sakae Okumura; Ken Nakagawa; Makoto Nishio; Takeshi Horai; Hiroyuki Aburatani; Masaaki Matsuura; Akinori Iwasaki; Yuichi Ishikawa
Journal:  Hum Pathol       Date:  2014-01-23       Impact factor: 3.466

6.  Small cell lung cancer tumors and preclinical models display heterogeneity of neuroendocrine phenotypes.

Authors:  Wei Zhang; Luc Girard; Yu-An Zhang; Tomohiro Haruki; Mahboubeh Papari-Zareei; Victor Stastny; Hans K Ghayee; Karel Pacak; Trudy G Oliver; John D Minna; Adi F Gazdar
Journal:  Transl Lung Cancer Res       Date:  2018-02

7.  The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Authors:  Jordi Barretina; Giordano Caponigro; Nicolas Stransky; Kavitha Venkatesan; Adam A Margolin; Sungjoon Kim; Christopher J Wilson; Joseph Lehár; Gregory V Kryukov; Dmitriy Sonkin; Anupama Reddy; Manway Liu; Lauren Murray; Michael F Berger; John E Monahan; Paula Morais; Jodi Meltzer; Adam Korejwa; Judit Jané-Valbuena; Felipa A Mapa; Joseph Thibault; Eva Bric-Furlong; Pichai Raman; Aaron Shipway; Ingo H Engels; Jill Cheng; Guoying K Yu; Jianjun Yu; Peter Aspesi; Melanie de Silva; Kalpana Jagtap; Michael D Jones; Li Wang; Charles Hatton; Emanuele Palescandolo; Supriya Gupta; Scott Mahan; Carrie Sougnez; Robert C Onofrio; Ted Liefeld; Laura MacConaill; Wendy Winckler; Michael Reich; Nanxin Li; Jill P Mesirov; Stacey B Gabriel; Gad Getz; Kristin Ardlie; Vivien Chan; Vic E Myer; Barbara L Weber; Jeff Porter; Markus Warmuth; Peter Finan; Jennifer L Harris; Matthew Meyerson; Todd R Golub; Michael P Morrissey; William R Sellers; Robert Schlegel; Levi A Garraway
Journal:  Nature       Date:  2012-03-28       Impact factor: 49.962

8.  DNA methylation in small cell lung cancer defines distinct disease subtypes and correlates with high expression of EZH2.

Authors:  J T Poirier; E E Gardner; N Connis; A L Moreira; E de Stanchina; C L Hann; C M Rudin
Journal:  Oncogene       Date:  2015-03-09       Impact factor: 9.867

9.  Protein expression of TTF1 and cMYC define distinct molecular subgroups of small cell lung cancer with unique vulnerabilities to aurora kinase inhibition, DLL3 targeting, and other targeted therapies.

Authors:  Robert J Cardnell; Lerong Li; Triparna Sen; Rasha Bara; Pan Tong; Junya Fujimoto; Abbie S Ireland; Matthew R Guthrie; Sheila Bheddah; Upasana Banerjee; Nene N Kalu; You-Hong Fan; Scott J Dylla; Faye M Johnson; Ignacio I Wistuba; Trudy G Oliver; John V Heymach; Bonnie S Glisson; Jing Wang; Lauren A Byers
Journal:  Oncotarget       Date:  2017-09-01

10.  A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal.

Authors:  Guido Rindi; David S Klimstra; Behnoush Abedi-Ardekani; Sylvia L Asa; Frederik T Bosman; Elisabeth Brambilla; Klaus J Busam; Ronald R de Krijger; Manfred Dietel; Adel K El-Naggar; Lynnette Fernandez-Cuesta; Günter Klöppel; W Glenn McCluggage; Holger Moch; Hiroko Ohgaki; Emad A Rakha; Nicholas S Reed; Brian A Rous; Hironobu Sasano; Aldo Scarpa; Jean-Yves Scoazec; William D Travis; Giovanni Tallini; Jacqueline Trouillas; J Han van Krieken; Ian A Cree
Journal:  Mod Pathol       Date:  2018-08-23       Impact factor: 7.842

View more
  2 in total

1.  ASCL1 and DLL3 expressions and their clinicopathological implications in surgically resected pure small cell lung cancer: A study of 247 cases from the National Cancer Center of China.

Authors:  Chunfang Hu; Jiyan Dong; Li Liu; Jingbo Liu; Xujie Sun; Fei Teng; Xin Wang; Jianming Ying; Junling Li; Puyuan Xing; Lin Yang
Journal:  Thorac Cancer       Date:  2021-12-20       Impact factor: 3.500

2.  Prognostic Implications of Molecular Subtypes in Primary Small Cell Lung Cancer and Their Correlation With Cancer Immunity.

Authors:  Jing Qi; Jiaqi Zhang; Ningbo Liu; Lujun Zhao; Bo Xu
Journal:  Front Oncol       Date:  2022-03-02       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.